Universe Pharmaceuticals INC
UPC
$4.20
$0.4010.53%
NASDAQ
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.73M | 29.52M | 32.31M | 33.36M | 34.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.73M | 29.52M | 32.31M | 33.36M | 34.41M |
| Cost of Revenue | 19.17M | 20.58M | 21.99M | 21.07M | 20.15M |
| Gross Profit | 7.56M | 8.94M | 10.32M | 12.29M | 14.26M |
| SG&A Expenses | 10.26M | 9.57M | 8.89M | 11.64M | 14.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 36.20K | 66.30K | 96.40K | 97.80K | 99.20K |
| Total Operating Expenses | 32.14M | 33.99M | 35.84M | 40.12M | 44.40M |
| Operating Income | -5.42M | -4.47M | -3.53M | -6.76M | -9.99M |
| Income Before Tax | -16.55M | -10.20M | -3.85M | -7.44M | -11.04M |
| Income Tax Expenses | 2.00M | 2.16M | 2.31M | 1.23M | 148.60K |
| Earnings from Continuing Operations | -18.55 | -12.36 | -6.16 | -8.67 | -11.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.55M | -12.36M | -6.16M | -8.67M | -11.18M |
| EBIT | -5.42M | -4.47M | -3.53M | -6.76M | -9.99M |
| EBITDA | -4.92M | -3.97M | -3.02M | -6.25M | -9.49M |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |